3AAZ

Crystal structure of the humanized recombinant Fab fragment of a murine; antibody


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.271 
  • R-Value Work: 0.209 
  • R-Value Observed: 0.212 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment.

Robert, R.Streltsov, V.A.Newman, J.Pearce, L.A.Wark, K.L.Dolezal, O.

(2010) Protein Sci 19: 299-308

  • DOI: 10.1002/pro.312
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Alzheimer's disease is the most common form of dementia, affecting 26 million people worldwide. The Abeta peptide (39-43 amino acids) derived from the proteolytic cleavage of the amyloid precursor protein is one of the main constituents of amyloid pl ...

    Alzheimer's disease is the most common form of dementia, affecting 26 million people worldwide. The Abeta peptide (39-43 amino acids) derived from the proteolytic cleavage of the amyloid precursor protein is one of the main constituents of amyloid plaques associated with disease pathogenesis and therefore a validated target for therapy. Recently, we characterized antibody fragments (Fab and scFvs) derived from the murine monoclonal antibody WO-2, which bind the immunodominant epitope ((3)EFRH(6)) in the Abeta peptide at the N-terminus. In vitro, these fragments are able to inhibit fibril formation, disaggregate preformed amyloid fibrils, and protect neuroblastoma cells against oligomer-mediated toxicity. In this study, we describe the humanization of WO-2 using complementary determining region loop grafting onto the human germline gene and the determination of the three-dimensional structure by X-ray crystallography. This humanized version retains a high affinity for the Abeta peptide and therefore is a potential candidate for passive immunotherapy of Alzheimer's disease.


    Organizational Affiliation

    CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia. remy.robert@csiro.au



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Humanized recombinant Fab fragment of a murine; antibodyA, H229Homo sapiensMutation(s): 0 
Gene Names: IGHV2-5*08
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Humanized recombinant Fab fragment of a murine; antibodyB, L229Homo sapiensMutation(s): 0 
Gene Names: IGHJ4*01
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.271 
  • R-Value Work: 0.209 
  • R-Value Observed: 0.212 
  • Space Group: P 31
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 106.732α = 90
b = 106.732β = 90
c = 90.867γ = 120
Software Package:
Software NamePurpose
ADSCdata collection
PHASERphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2009-11-28 
  • Released Date: 2010-03-02 
  • Deposition Author(s): Streltsov, V.A.

Revision History 

  • Version 1.0: 2010-03-02
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Advisory, Version format compliance